Home/Ingredients/Adaptogens/Ashwagandha (generic)
⚑ Unstandardised — caution FSSAI Permitted India availability: Very high Evidence: Limited

Ashwagandha
(generic powder)

The version of ashwagandha that accounts for the majority of Indian supplement sales. Dried, ground Withania somnifera root with no withanolide standardisation, no extraction process, and no RCT conducted on the actual powder. You are not getting KSM-66 outcomes at KSM-66 doses. The 27 RCTs everyone cites were not run on this product.

Updated: May 2026~14 min read15 citations
<1%
Typical withanolide content in generic root powder. KSM-66 is standardised to ≥5%. The active molecule content is 5× lower at the same dose.
0
Rigorous double-blind RCTs conducted specifically on unstandardised Withania somnifera root powder at supplement doses. All cited studies used standardised extracts.
150–₹500
Per month for generic powder (May 2026, Amazon.in). Compared to ₹400–₹700 for KSM-66 — the price difference is not worth the evidence gap.
3–5×
Lower withanolide delivery at equivalent label doses vs KSM-66. The "500mg" on both labels does not represent equivalent bioactive content.
On this page

What is generic ashwagandha powder?

Generic ashwagandha powder is dried and ground Withania somnifera root — the whole root, processed minimally and encapsulated or packaged without extraction, concentration, or bioactive standardisation. It is the form ashwagandha has taken in Ayurvedic medicine for over 3,000 years, used in preparations called churna (powder), leha (electuary), and kwatha (decoction). [1]

In the modern supplement market, this same material is sold in 500mg capsules or 1kg bulk bags under dozens of brand names across Amazon India, Flipkart, and offline pharmacy chains — often at ₹150–500 per month. The marketing on these products frequently references the same clinical trial data that applies exclusively to standardised ashwagandha extracts (KSM-66, Sensoril, Shoden) — a practice that misrepresents the evidence and misleads buyers. [2]

The standardisation problem — what the label does not tell you

The central issue with generic ashwagandha powder is withanolide content variability. Withanolides are the primary bioactive steroidal lactones in Withania somnifera — specifically withanolide A, withaferin A, and withanolide D — responsible for the GABA-A receptor potentiation, cortisol modulation, and androgenic effects documented in clinical trials. [3]

In raw root powder, withanolide concentration varies enormously depending on: plant ecotype and genetics, soil composition, harvest season (withanolide content peaks post-monsoon), plant part ratio (leaves contain more withanolides than roots, but also more withaferin A, which has cytotoxic properties), and storage and processing conditions. Published analyses of commercial ashwagandha preparations find total withanolide content ranging from 0.13% to 1.2% in raw root powder — compared to the ≥5% guaranteed in KSM-66. [4]

At a 600mg daily dose: generic powder delivers approximately 0.8–7.2mg withanolides. KSM-66 at the same dose delivers ≥30mg. The clinical trials showing cortisol reduction, testosterone increase, and stress attenuation used 300–600mg of KSM-66 — delivering 15–30mg withanolides per dose. The label dose is not the active dose. [5]

The marketing deception in one sentence

Supplement labels say: "Ashwagandha root extract 500mg — supports stress, cortisol, and testosterone." The cited studies were conducted on KSM-66 at ≥5% withanolides. Generic powder at 500mg contains ~0.5–6mg withanolides — roughly 5–60× below the clinical dose. The "500mg" number on both labels refers to total powder weight, not equivalent bioactive content. This is not illegal — it is a gap in FSSAI labelling regulations — but it is systematically misleading. [6]

Active compounds — what withanolides do

The pharmacology of Withania somnifera is driven by three classes of bioactives: withanolides (steroidal lactones), alkaloids (withanine, somniferine), and sitoindosides (glycowithanolides). The withanolides are the primary evidence-backed compounds. [3]

GABA-A potentiation: Withanolide A and sitoindosides act as positive allosteric modulators of GABA-A receptors, enhancing inhibitory neurotransmission. This is the primary mechanism behind the anxiolytic and sleep-onset effects. Unlike benzodiazepines, this effect does not cause dependence or tolerance at therapeutic doses in animal models. [7]

HPA axis suppression: Withanolides reduce hypothalamic CRH secretion and anterior pituitary ACTH release, lowering basal cortisol and attenuating the cortisol spike in response to stressors. This is the mechanism behind the adaptation and stress-resilience effects documented in KSM-66 trials. [8]

LH/testosterone pathway: Reduced cortisol disinhibits hypothalamic GnRH secretion, increasing LH and downstream Leydig cell testosterone production. Wankhede et al. 2015 documented +17% testosterone at 300mg BID KSM-66 — this is a cortisol-mediated indirect effect, not direct androgenic stimulation. Insufficient withanolide delivery from generic powder means this pathway is unlikely to be meaningfully activated. [9]

KSM-66 / Sensoril ≥5% withanolides ✓ Clinical dose met Generic powder <1% withanolides ✗ 5–60× below clinical dose MECHANISM GABA-A potentiation ↑ HPA axis → CRH/ACTH ↓ Cortisol ↓ GnRH → LH → T ↑ OUTCOMES ✓ Verified (KSM-66 RCTs) ? Unknown (generic) No RCT conducted Standardised extract pathway (evidence-backed) Generic powder pathway (assumed, not tested)
Fig. 1 — Standardised extract vs generic powder: the same mechanism, but only one form reaches the bioactive threshold documented in clinical trials.

Evidence audit — what actually applies to generic powder

The table below distinguishes studies by the specific form of ashwagandha used. This is the audit most supplement brands do not want you to run.

StudyForm usedApplies to generic powder?Key findingGrade
Wankhede et al. (2015) — JISSN
doi:10.1186/s12970-015-0104-9
KSM-66 300mg BID ✗ No +17% testosterone, +15% muscle recovery, +18% VO₂ max vs placebo. Standardised extract only. A
Langade et al. (2019) — Cureus
doi:10.7759/cureus.6028
KSM-66 300mg BID ✗ No Significant improvement in sleep quality, onset latency, and total sleep time vs placebo (double-blind RCT). A
Chandrasekhar et al. (2012) — IJAYM
doi:10.4103/0974-8520.110555
KSM-66 300mg BID ✗ No -27.9% serum cortisol vs placebo in chronically stressed adults. The most-cited ashwagandha cortisol study. A
Bhattacharya et al. (2000) — Phytomedicine
doi:10.1016/S0944-7113(00)80030-6
Withanolide-standardised extract (not KSM-66) ~ Partial Anxiolytic effect in animal models. Standardised but older extract — applicable if withanolide content is verified. Not raw powder. B
Traditional use / Ayurvedic texts (Charaka Samhita, Ashtanga Hridayam) Whole root churna (powder) ✓ Yes Traditional Rasayana use at 3–6g daily churna with warm milk and honey. Historical use as a general tonic, not for specific clinical outcomes. Mechanistic but not RCT-level evidence. C

When generic powder is the right choice

Traditional Ayurvedic use — specifically churna preparations at 3–6g daily with warm milk, ghee, or honey as anupana (carrier) — is legitimate and historically grounded. If you are an Ayurvedic practitioner or following a classical formulation, generic root powder in these preparations is appropriate. The problem is specifically when it is marketed and dosed as an equivalent to standardised extracts in clinical supplement protocols. [1]

Dosage reality for generic powder

The Ayurvedic classical dose for ashwagandha churna is 3–6g per day, taken with warm milk, ghee, or honey as adjuvant — not 300–600mg capsules. At 5g of generic root powder with ~0.5–1% withanolides, you deliver approximately 25–50mg withanolides — approaching the range used in clinical trials. At the typical Indian supplement capsule dose of 500mg generic powder, you deliver 2.5–6mg withanolides — roughly 5–10× below the clinical threshold. [10]

The practical implication: if you want to use generic ashwagandha powder for evidence-backed clinical endpoints, the correct dose is 3–6g daily in warm milk, not 1–2 × 500mg capsules. At that dose and preparation, you may approach clinical relevance. At the typical capsule dose, you are likely below the threshold for measurable effect. [11]

Generic powder vs KSM-66 vs Sensoril

This ingredient
Generic powder
Withanolides<1% (unverified)
RCTs on this form0
Clinical dose (supplement)3–6 g/day churna
India price/month₹150–₹500
Appropriate useAyurvedic churna
Best choice for clinical use
KSM-66
Withanolides≥5% (standardised)
RCTs on this form27+
Clinical dose300–600 mg/day
India price/month₹400–₹700
Appropriate useAll clinical endpoints
Best for anxiety/sleep
Sensoril
Withanolides≥8% (root+leaf)
RCTs on this form11+
Clinical dose125–250 mg/day
India price/month₹500–₹900
Appropriate useAnxiety, sleep endpoints

India-specific context

🇮🇳 India market data

The highest-volume, lowest-evidence ashwagandha category

₹150–₹500
Per month for generic ashwagandha powder (May 2026). The price is compelling — but evidence-per-rupee is the relevant metric, not price alone.
80%+
Estimated share of Indian ashwagandha supplement sales that are generic powder, not standardised extract. Most consumers do not know the difference.
FSSAI ✓
Permitted under Schedule II as a traditional herbal ingredient. No withanolide standardisation requirement exists under current FSSAI regulations — a gap that enables the evidence-to-label mismatch.

India is one of the world's largest producers of Withania somnifera, with cultivation concentrated in Madhya Pradesh, Rajasthan, and Uttar Pradesh. This makes raw root powder extremely cheap — often ₹100–300 per kg at wholesale. The commercial supplement form passes through minimal processing before being encapsulated and labelled with claims lifted directly from KSM-66 clinical trials. [12]

FSSAI's Health Supplement Regulations (2022) require ingredients to be on the permitted list and within general safety guidelines — but do not mandate that efficacy claims be supported by evidence on the actual formulation being sold. A brand can legally cite a KSM-66 cortisol trial to support a claim made for its generic ashwagandha powder product. This is the regulatory gap that enables the current market situation. [13]

Lab test data

PhytoChemia / independent analysis
Commercial ashwagandha audit
Wide withanolide variability found
Range in tested products0.13%–1.2% withanolides
Products meeting ≥5% claim0% (without extraction)
Withaferin A (potentially cytotoxic at high dose) detectedVariable
Variability in withanolide content between batches and producers is the defining quality problem for generic powder. [4]
NABL lab testing — India market
Generic powder COA audit
COA rarely published
Brands with published batch COAs<5 found
Heavy metal testing publishedRare
Withanolide-specific testingEssentially none
Generic powder brands almost universally do not publish independent NABL COAs with withanolide-specific data. "Lab tested" on a label usually refers to basic adulterant screening, not bioactive quantification.
Heavy metals — specific concern
Indian soil contamination risk
Lead and arsenic detected in some products
Lead exceedances (historic India data)Documented in literature
Arsenic risk (agricultural soil)Region-dependent
ConsumerLab / USP screeningMultiple failures historically
Heavy metal contamination in Indian-sourced herbal powders is a documented public health concern. Standardised extracts (KSM-66, Sensoril) include heavy metal screening as part of their quality programme. Generic powders typically do not. [14]

Indian brand comparison

Brand & product₹/monthFormWithanolide dataOur take
Patanjali Ashwagandha Churna₹70–₹120Root powder churnaNot specifiedTraditional churna format — appropriate for Ayurvedic use at 3–6g/day in warm milk. Do not use for clinical supplement purposes at low capsule doses.
Himalaya Ashvagandha tablet₹120–₹180Dry root extract (2.5% withanolides)2.5% claimed — partial standardisationPartial standardisation — better than pure powder, weaker than KSM-66. No NABL COA published for batch verification. Marketing claims exceed evidence for this concentration.
Organic India Ashwagandha₹200–₹300Certified organic root powderWithanolide content not statedOrganic certification addresses pesticide concern but does not address withanolide standardisation. Not equivalent to KSM-66.
AS-IT-IS Ashwagandha (generic)₹180–₹280Root powder — unflavouredNo withanolide data publishedTransparent brand for other products but this product is unstandardised. Good for traditional Ayurvedic use at high doses, not supplement clinical use.
Generic Amazon private label ashwagandha₹150–₹350Unknown — usually root powderNo COA, no withanolide dataAvoid entirely. No quality data, no standardisation, no batch verification. The cost savings vs KSM-66 (₹200–300/month) do not justify the evidence gap.

Related conditions

Traditional use

Ayurvedic Rasayana therapy

Generic ashwagandha powder has 3,000+ years of traditional use as a Rasayana — a rejuvenating formulation. Classical preparations combine 3–6g churna with warm cow's milk, ghee, honey, or mishri as anupana. This is the appropriate context for generic powder. If you are an Ayurvedic practitioner or following a classical protocol, this form is legitimate and historically grounded. [1]

Stress / Cortisol

Chronic stress — use standardised extract instead

All clinical evidence for cortisol reduction is from KSM-66 or Sensoril at ≥5% withanolides. Generic powder at 500–600mg daily delivers an estimated 2.5–6mg withanolides — 5–10× below the effective dose in Chandrasekhar et al. 2012. For stress management, upgrade to KSM-66. The extra ₹200–300/month has clinical justification. [8]

Pregnancy / Lactation

Contraindicated — avoid all ashwagandha forms

Ashwagandha has documented abortifacient properties in animal models at high doses due to withanolide-mediated uterine stimulation. All forms — generic and standardised — should be avoided during pregnancy. Widely sold in Indian markets as a "tonic" without clear pregnancy warnings. FSSAI should be notified if pregnancy claims are made without contraindication disclosure.

Thyroid conditions

Caution — monitor thyroid function

Ashwagandha has been shown to increase T3 and T4 in subclinical hypothyroidism RCTs. For individuals with normal thyroid function, this is generally not a concern at supplement doses. For hyperthyroid patients or those on thyroid medication (levothyroxine), withanolide supplementation requires physician oversight regardless of the ashwagandha form. [15]

Commonly taken together

Warm milk (anupana)

Traditional synergy

The classical Ayurvedic preparation is ashwagandha churna dissolved in warm cow's milk with ghee or honey. Milk fat improves lipophilic withanolide absorption; the warm temperature aids bioavailability. If using generic powder in traditional context, this is the correct preparation — not cold water or plain capsules. 3–6g in 200ml warm milk at bedtime is the classical protocol. [1]

Black pepper / piperine

Bioavailability support

Piperine inhibits intestinal P-glycoprotein and CYP3A4, modestly improving absorption of lipophilic compounds including withanolides. Some Indian traditional preparations include black pepper (krishna) as an adjuvant. Adding a small amount of piperine (5mg) may partially compensate for the low bioavailability of generic powder, but does not solve the fundamental low-withanolide-content problem.

Shatavari (for female use)

Traditional combination

Classical Ayurvedic female Rasayana formulas combine ashwagandha and shatavari (Asparagus racemosus) as complementary tonics — ashwagandha for strength and cortisol modulation, shatavari for reproductive and hormonal support. This pairing is traditional rather than RCT-backed but represents coherent traditional pharmacology. Both are available cheaply in India.

Upgrade to KSM-66 instead

Best action

If you are currently taking generic ashwagandha powder for cortisol, stress, sleep, or testosterone outcomes — the most impactful "stack" is to replace it with KSM-66. The price difference is ₹200–300/month; the evidence gap is 27 RCTs vs 0. Nakpro KSM-66 and OZiva KSM-66 are the most cost-effective Indian-market options for the standardised extract. See our KSM-66 page for full comparison.

Scoring rubric — full breakdown

1. Evidence quality

2.0/10

Zero double-blind RCTs conducted specifically on unstandardised generic ashwagandha powder at supplement doses. All high-quality evidence in the literature applies to KSM-66 or Sensoril. Traditional use data exists and is relevant in its appropriate context, but cannot substitute for RCT evidence when clinical outcomes are being marketed. The score of 2.0 reflects the complete absence of applicable clinical trial evidence at supplement capsule doses. [2]

2. Dosage confidence

2.5/10

With variable withanolide content and no standardisation, you cannot confidently dose generic powder for a clinical endpoint. The traditional dose (3–6g daily churna) is well-established for Ayurvedic use. The modern capsule dose (500–600mg) is not established by any RCT as effective. You score 2.5 because traditional dosing guidance is clear, but clinical supplement dosing is essentially undefined. [10]

3. India market fit

6.0/10

India produces most of the world's ashwagandha. Generic powder is abundantly available, cheap, and culturally embedded — Patanjali churna is sold in every kirana store. For traditional Ayurvedic household use at correct doses (3–6g in warm milk), this is the appropriate form, not a capsule of standardised extract. The score of 6.0 reflects excellent availability and cultural fit in the traditional use context, penalised for being systematically misrepresented as equivalent to standardised extracts in the modern supplement market.

4. Safety profile

7.0/10

Ashwagandha root powder has a multi-century safety record in traditional use. At capsule doses (500mg–1g daily), adverse events are uncommon — primarily GI discomfort and, rarely, hepatotoxicity at very high doses. Deducting points for: (a) pregnancy contraindication frequently not disclosed on Indian products; (b) heavy metal contamination risk in unverified Indian-sourced powder; (c) thyroid interaction requiring physician awareness. Safety at traditional Ayurvedic doses is generally well-established. [15]

5. Label accuracy (tested products)

3.5/10

Almost no Indian generic ashwagandha product publishes NABL-accredited COA data with withanolide quantification. The market ranges from Patanjali churna (at least honest about being a traditional preparation) to anonymous Amazon private-label capsules making KSM-66-quality claims. The regulatory gap allowing clinical efficacy claims to be made without corresponding extract standardisation is the fundamental problem. Score 3.5 reflects the absence of verifiable quality data and the widespread use of clinical trial evidence from a different, higher-quality form.

References

  1. 1
    Charaka Samhita, Chikitsa Sthana 1.3.30–38. Classical Ayurvedic text, ~300–700 CE. Referenced in: Mishra LC (ed). Scientific Basis for Ayurvedic Therapies. CRC Press; 2004. ISBN:0849313333.
  2. 2
    Pratte MA, et al. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med. 2014;20(12):901–8.doi:10.1089/acm.2014.0177
  3. 3
    Mirjalili MH, et al. Steroidal lactones from Withania somnifera: an overview. Molecules. 2009;14(7):2373–93.doi:10.3390/molecules14072373
  4. 4
    Tandon N, Yadav SS. Safety and clinical effectiveness of Withania somnifera (Linn.) Dunal root in human ailments. J Ethnopharmacol. 2020;255:112768.doi:10.1016/j.jep.2020.112768
  5. 5
    Wankhede S, et al. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr. 2015;12:43.doi:10.1186/s12970-015-0104-9
  6. 6
    Food Safety and Standards Authority of India. Health Supplements, Nutraceuticals, Food for Special Dietary Use Regulations, 2022. Schedule II — Permitted ingredients and claims framework.FSSAI Official Gazette
  7. 7
    Mehta AK, et al. Pharmacological effects of Withania somnifera root extract on GABA-A receptor complex. Indian J Med Res. 1991;94:312–5. PMID:1774991.
  8. 8
    Chandrasekhar K, et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255–62.doi:10.4103/0253-7176.106022
  9. 9
    Wankhede S, et al. (2015). Op. cit. [5]
  10. 10
    Singh N, et al. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208–13.doi:10.4314/ajtcam.v8i5S.9
  11. 11
    Borse SP, et al. Phytochemical analysis and anti-SARS-CoV-2 activity of Withania somnifera root powder and root extract. J Ayurveda Integr Med. 2023;14(2):100681.doi:10.1016/j.jaim.2023.100681
  12. 12
    Patel SB, et al. Cultivation and trade of Withania somnifera in India. Industrial Crops and Products. 2016;80:244–252.doi:10.1016/j.indcrop.2015.10.060
  13. 13
    FSSAI. Health Supplement Regulations 2022. Op. cit. [6]
  14. 14
    Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol. 2002;57(12):891–6.doi:10.1007/s00228-001-0400-y
  15. 15
    Sharma AK, et al. Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med. 2018;24(3):243–248.doi:10.1089/acm.2017.0183

Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy